Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors
Tóm tắt
We examined new users of osteoporosis drugs among seniors in Pennsylvania and found no evidence of healthy adherer bias on observed associations between adherence to treatment and non-vertebral fracture risk; we document fracture reduction with better adherence to bisphosphonates, yet no fracture reduction with better adherence to calcitonin or raloxifene. We examined the potential for “healthy adherer bias” when studying the effects of adherence to osteoporosis pharmacotherapy on fracture risk. Based on clinical trial evidence, bisphosphonates, calcitonin, and raloxifene reduce vertebral fracture risk; yet only bisphosphonates are documented to reduce non-vertebral fracture risk. This is a cohort study of older women in Pennsylvania who initiated osteoporosis drugs between 1995 and 2005. We included new users of bisphosphonates, calcitonin, and raloxifene. Adherence was categorized based on a measure of compliance as high [proportion of days covered (PDC) ≥ 80%], intermediate (50% < PDC < 80%), or low (PDC ≤ 50%) according to a 180-day ascertainment period. Non-vertebral fracture rates within 365 days after the ascertainment period were compared between adherence categories (reference = low) using Cox proportional hazard models and adjusting for fracture risk factors. Primary and secondary prevention cohorts were examined separately. Adherence to calcitonin and raloxifene were control analyses. We found little difference in fracture rates between levels of adherence to calcitonin, bisphosphonates for primary prevention, or raloxifene for secondary prevention. We document lower fracture rates among high versus low adherent bisphosphonate users for secondary prevention (HR = 0.53, 95%CI = 0.38–0.74) and higher fracture rates among high versus low adherent raloxifene users for primary prevention (HR = 2.01, 95%CI = 1.04–3.87). We document little evidence of healthy adherer bias when studying the association between better adherence to osteoporosis drugs and fracture risk reduction, with only better adherence to bisphosphonates reducing fracture risk. The higher fracture risk among highly adherent raloxifene users for primary prevention is likely due to residual confounding.
Tài liệu tham khảo
Burge R, Dawson-Hughes B, Solomon DH et al (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475
MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213
Kothawala P, Badamgarav E, Ryu S et al (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501
Siris ES, Selby PL, Saag KG et al (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13
Wilkes MM, Navickis RJ, Chan WW et al (2010) Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int 21:679–688
Rabenda V, Hiligsmann M, Reginster JY (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303–2315
Imaz I, Zegarra P, Gonzalez-Enriquez J et al. (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. doi:10.1007/s00198-00009-01134-00194
Granger BB, Swedberg K, Ekman I et al (2005) Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366:2005–2011
Simpson SH, Eurich DT, Majumdar SR et al (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15
Curtis J, Larson J, Delzell E et al (2009) Does the benefit of medication adherence relate more to a drug effect or the behavior itself? Quantifying the effect of adherence behavior using data from the placebo arms of the WHI. Arthritis Rheum 60(Suppl 10):613 (abstract)
American College of Physicians (2008) Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 148:956–961
Rasmussen JN, Chong A, Alter DA (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. Jama 297:177–186
Janz NK, Champion VL, Strecher VJ (2002) The health belief model. In: Glanz K, Rimer BK, Lewis FM (eds) Health behavior and health education: theory, research, and practice. Jossey-Bass, San Francisco, pp 45–66
DiMatteo MR, Haskard KB, Williams SL (2007) Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 45:521–528
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497
Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47
Peterson AM, Nau DP, Cramer JA et al (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3–12
Cadarette SM, Burden AM (2010) Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol. doi:10.1097/BOR.0b013e32833ac7fe
Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468
Suissa S (2008) Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008:329–335
Ray WA, Griffin MR, Fought RL et al (1992) Identification of fractures from computerized Medicare files. J Clin Epidemiol 45:703–714
Cadarette SM, Katz JN, Brookhart MA et al (2008) Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637–646
Foster SA, Foley KA, Meadows ES et al (2008) Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health 8:24
Pickney CS, Arnason JA (2005) Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 16:1156–1160
Brookhart MA, Patrick AR, Avorn J et al (2007) Adherence to lipid-lowering therapy and the use of preventive health care services: an investigation of the healthy user effect. Am J Epidemiol 120:251–256
Dormuth CR, Patrick AR, Shrank WH et al (2009) Statin adherence and risk of accidents: a cautionary tale. Circulation 119:2051–2057
Giangregorio L, Dolovich L, Cranney A et al (2009) Osteoporosis risk perceptions among patients who have sustained a fragility fracture. Patient Educ Couns 74:213–220
Sale JEM, Beaton DE, Sujic R et al. (2010) “If it was osteoporosis, I would have really hurt myself.” Ambiguity about osteoporosis and osteoporosis care despite a screening program to educate fragility fracture patients. J Eval Clin Pract 16:590–596
Holick MF, Siris ES, Binkley N et al (2005) Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215–3224
Miller PD, Derman RJ (2010) What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int. doi:10.1007/s00198-010-1208-3
Brookhart MA, Avorn J, Katz JN et al (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251–256
Roughead EE, Ramsay E, Priess K et al (2009) Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates. Pharmacoepidemiol Drug Saf 18:69–75